Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | CBFB | Q13951 | 1/20 | 0.52 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128905 | 0.86 | GAA (0.50) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL666767 | 0.86 | NPBWR1 (0.43) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL2418844 | 0.82 | SCN10A (0.61) | KCNH2DYRK1ASCN10A | |
| SCHEMBL10694441 | 0.80 | KDM4E (0.65) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL3885700 | 0.79 | NPBWR1 (0.55) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL30672494 | 0.79 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL21500616 | 0.79 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL2107034 | 0.79 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL12020707 | 0.79 | MAPT (0.76) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL2711965 | 0.79 | DGAT1 (0.61) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115945180-B | Adsorbent for refining hexafluoro-1, 3-butadiene and preparation method and application thereof | 天津绿菱气体股份有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-115945180-A | Adsorbent for refining hexafluoro-1, 3-butadiene and preparation method and application thereof | 天津绿菱气体有限公司 | 2023-04-11 | — | — | CN | claimed |
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL SCIENT IND RES (IN) | 2026-02-12 | — | — | US | disclosed |
| CN-118063453-B | Benzimidazole derivative, preparation method and application thereof, and agricultural bactericide | 南京吉星生物技术开发有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-115945180-B | Adsorbent for refining hexafluoro-1, 3-butadiene and preparation method and application thereof | 天津绿菱气体股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118063453-A | Benzimidazole derivative, preparation method and application thereof, and agricultural bactericide | 南京吉星生物技术开发有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-02-15 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| CN-115945180-A | Adsorbent for refining hexafluoro-1, 3-butadiene and preparation method and application thereof | 天津绿菱气体有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-5077407-A | Substituted 2-[monoannelated (3,4-,4,5-, and 5,6-) pyridylalkylenesulfinyl]benzimidazoles | THE UPJOHN COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
| EP-0130729-A2 | Alkylthio- and alkylsulfinyl-benzimidazole derivatives | THE UPJOHN COMPANY (US) | 1985-01-09 | — | — | EP | disclosed |
| US-4472409-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535607-B2 | Isoindolines as HDAC inhibitors | HDAC1, HDAC2, HDAC3 | NPBWR1 2624/4885DGAT1 3564/4885KCNH2 1422/4885 |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | NPBWR1 1041/4885DGAT1 34/4885KCNH2 2975/4885 |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | NPBWR1 2819/4885DGAT1 3639/4885KCNH2 1378/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | NPBWR1 921/4885DGAT1 3534/4885KCNH2 4016/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | NPBWR1 427/4885DGAT1 2689/4885KCNH2 371/4885 |
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPBWR1 1928/4885DGAT1 1032/4885KCNH2 2622/4885 |
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | ACE2, SARS1, NR3C2 | NPBWR1 717/4885DGAT1 1533/4885KCNH2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.